Program
luprolide acetate gel depot
Also written as “Leuprolide Open Label”, “Eligard® 45 mg” and “Eligard”.
Its studies are mostly in Prostatic Neoplasms, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Daewoong Pharmaceutical | 21 open or running | phase 4since Jan 13, 2012 | Jan 13, 2012 | none ahead |
| Astellas Pharma | 10 open or running | phase 4since Aug 28, 2013 | Aug 28, 2013 | none ahead |
| Pfizer | 11 open or running | phase 3since Dec 14, 2014 | Dec 14, 2014 | none ahead |
Also a collaborator on its studies: Medivation LLC, a wholly owned subsidiary of Pfizer.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 13, 2012First study: phase 4 study in Prostatic NeoplasmsNew to Daewoong PharmaceuticalDaewoong Pharmaceutical · NCT01511874 · 42 enrolled · Korea, Republic of
- Aug 28, 2013Astellas Pharma’s first study: phase 4 study in Prostatic NeoplasmsNew to Astellas PharmaAstellas Pharma · NCT01933022 · 1 enrolled · Netherlands
- Dec 14, 2014Pfizer’s first study: phase 3 study in Prostatic NeoplasmsNew to PfizerPfizer · NCT02319837 · 1,068 enrolled · United States, Australia, Austria and more
- Apr 8, 2025Phase 4 study in CPPDaewoong Pharmaceutical · NCT06926933 · 50 enrolled · South Korea
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06926933CPP · South Korea | 4 | Active, not recruiting | Daewoong Pharmaceutical | Jun 15, 2026 | 50 |
| NCT02319837Prostatic Neoplasms · United States, Australia, Austria and more | 3 | Active, not recruiting | Pfizer | Jan 31, 2023 | 1,068 |
| NCT01933022Prostatic Neoplasms · Netherlands | 4 | Terminated | Astellas Pharma | Aug 2015 | 1 |
| NCT01511874Prostatic Neoplasms · Korea, Republic of | 4 | Completed | Daewoong Pharmaceutical | May 2013 | 42 |
How it is read
Names in the registry
- “Leuprolide Open Label”, 1 entry
- “Eligard® 45 mg”, 1 entry
- “Eligard”, 1 entry
- “ELIGARD 22.5mg”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.